Phathom Pharmaceuticals, Inc.
Investors that purchased the Company’s securities and have suffered a loss, please fill in transaction information below, or email to info@portnoylaw.com.
There is no cost or obligation associated with submitting your information. If you are a shareholder who suffered a loss, please submit your contact information and purchase information to participate in the putative class action.
We also encourage you to contact Lesley F. Portnoy of The Portnoy Law Firm, at 310.692.8883, to discuss your rights free of charge. You can also reach us through the firm’s website at www.portnoylaw.com, or by email at info@portnoylaw.com.
If you choose to take no action, you can remain an absent class member.
Joining the case through the Portnoy Law website enables investors to learn about their legal claims and take an active role in recovering their losses.
The Portnoy Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
CONTACT:
Portnoy Law Firm
Lesley F. Portnoy, Esq.,
www.portnoylaw.com
Office: 310.692.8883
1800 Century Park East, Suite 600
Los Angeles, CA 90067
info@portnoylaw.com
Phathom Pharmaceuticals issued a press release titled “Phathom Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Updates” on August 2, 2022, prior to market hours. The press release disclosed that during post-approval testing for the commercial launch of their vonoprazan drug product, the company found trace levels of a nitrosamine impurity. Phathom is currently collaborating with the FDA to implement an additional test method, specification, acceptable intake limit, and controls to address this issue before releasing their first vonoprazan-based products to the market. As a result, the VOQUEZNA DUAL PAK and VOQUEZNA TRIPLE PAK product launches will be delayed. This news caused Phathom’s stock price to drop by 28% or $2.61 per share to close at $6.46 per share on August 2, 2022.
